| Title: | Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : final analysis of the GioTag study |
|---|
| Authors: | ID Hochmair, Maximilian J (Author)
ID Morabito, Alessandro (Author)
ID Hao, Desiree (Author)
ID Yang, Cheng-Ta (Author)
ID Soo, Ross A (Author)
ID Yang, James C-H (Author)
ID Gucalp, Rasim (Author)
ID Halmos, Balazs (Author)
ID Märten, Angela (Author)
ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Author) |
|---|
| Files: |  PDF - Presentation file, download (1,58 MB)
MD5: E5B817D1334C093553F6EC429C0A7178
PDF - Supplement, download (1,10 MB)
MD5: C384BC86E3FD51111A4BAD50BC370759
 URL - Source URL, visit https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-0740
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
|
|---|
| Abstract: | Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment >/=10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. |
|---|
| Keywords: | non-small cell lung carcinoma -- therapy, drug therapy, afatinib, osimertinib, GioTag study |
|---|
| Publication status: | In print |
|---|
| Publication version: | Version of Record |
|---|
| Place of publishing: | Velika Britanija |
|---|
| Publisher: | Future Medicine Ltd |
|---|
| Year of publishing: | 2020 |
|---|
| Number of pages: | str. [1-10] |
|---|
| Numbering: | Vol. 16, no. |
|---|
| PID: | 20.500.12556/DiRROS-12685  |
|---|
| UDC: | 616-006 |
|---|
| ISSN on article: | 1744-8301 |
|---|
| DOI: | 10.2217/fon-2020-0740 |
|---|
| COBISS.SI-ID: | 37424899 |
|---|
| Copyright: | © 2020 Maximilian J. Hochmair and other authors |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 14. 11. 2020;
Soavtorica iz Slovenije: Tanja Cufer;
|
|---|
| Publication date in DiRROS: | 18.11.2020 |
|---|
| Views: | 1919 |
|---|
| Downloads: | 1498 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
